You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Developmental Neurotox Assay using Scalable Neurons and Astrocytes in High Content Imaging

    SBC: Aruna Biomedical, Inc.            Topic: B

    There is unmet need for rapid, cost effective in vitro methods to identify chemicals that pose a hazard to the human brain. A number of in vitro assays utilizing primary cells have been tested in an effort to devise effective models to prioritize chemicals for further in depth toxicity studies. However, isolation of primary human neural tissue is cost and labor intensive, and cannot be produced in ...

    SBIR Phase II 2014 Environmental Protection Agency
  2. Development of Novel Targeted Therapy for Prostate Cancer

    SBC: Sophia Bioscience Inc            Topic: NCI

    DESCRIPTION (provided by applicant): Prostate cancer (PCa) is the most diagnosed cancer among men in developed countries including the United States with significant medical cost burdens. Tremendous advances have been made in PCa screening technologies, which allow early detection and treatment. Common treatment options include radical prostatectomy, external beam radiation therapy (RT) and inters ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. VLR-CART Cancer Immunotherapy

    SBC: Novab, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The mission of Novab is to utilize the unique properties of lamprey generated Variable Lymphocyte Receptors (VLRs) to develop effective, complementary and/or superior therapeutics to those currently derived from mammalian monoclonal antibodies (mMAbs). In the current application, we seek to initiate and demonstrate proof of concept for one commercial project w ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain

    SBC: HALIMED PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Improving Articulatory Precision in Neurologically Compromised Adults Using Audio

    SBC: Bionic Sciences Inc.            Topic: NIDCD

    DESCRIPTION (provided by applicant): Improving Articulatory Precision in Neurologically Compromised Adults Using Audiovisual Biofeedback. One of the most frustrating impairments of neurological damage is the inability to communicate properly via the speechmodality due to weakness in the oral motor structures, also known as dysarthria. We propose to develop a Tongue Tracking System (TTS) that can p ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Engineered Neurotensin Fragments Targeting Neuropathic Pain

    SBC: JT Pharmaceuticals, Inc.            Topic: NIDCR

    DESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications, including opioids and non-opioids (primarily NSAIDs), have major side effects associated with their use, and many individuals donot respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as an alternative; however, the only succ ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a lasmiditan analogue for treatment of acute kidney injury

    SBC: Mitohealth, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe and efficacious therapeutic small molecule for treatment of acute kidney injury (AKI). AKI results from diverse insults such as sepsis, ischemia-reperfusion (I/R)or nephrotoxicant exposure and nearly half of those who develop AKI do not survive. Since treatment remains largely palliative and survival rates ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. On-chip OCT for Ophthalmology applications

    SBC: Sinoora Inc.            Topic: NIBIB

    DESCRIPTION (provided by applicant): Sinoora Inc. proposes to develop an on-chip spectral domain-optical coherence tomography (SD-OCT) system for ophthalmic applications. Phase I will concentrate on demonstrating the passive optical components of the OCT system on a single chip. The passive components include a spectrometer, coupler and an interferometer. These on- chip components will then be int ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Hydrocyanine Probes for the Accurate Detection of Reactive Oxygen Species

    SBC: LI-COR BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Reactive oxygen species (ROS) are involved in numerous cell-signaling pathways. They have been implicated in over 150 diseases including cancer, arthritis, Parkinson's disease, diabetes, myocardial infarction and atherosclerosis. The need to understand the role of ROS in these processes is evidenced by the 80,000 publications in this field during the last ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Antibodies to O-GlcNAc modified histones for chromatin biology and epigenetic res

    SBC: GlycoScientific, L.L.C.            Topic: NIGMS

    DESCRIPTION (provided by applicant): O-glycosylation of nuclear and cytoplasmic proteins by a single ?-N-acetyl-D-glucosamine moiety (O-GlcNAc) is a common post-translational modification that is highly dynamic and fluctuates in response to cellular stimuli. This type of glycosylation has been found on approximately a thousand human proteins to date, and is thought to be nearly as wide-spread and ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government